BALTIMORE--(BUSINESS WIRE)--KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, today announced it has closed an investment from New York Blood Center, Inc. (NYBC).
Researchers have made huge strides in ensuring that red blood cell substitutes -- or artificial blood -- are able to work safely and effectively when transfused into the bloodstream. Researchers have ...
CHICAGO, May 23 (Reuters) - Northfield Laboratories Inc. said on Wednesday that its red blood cell substitute, PolyHeme, failed to meet the primary goals of mortality and safety in a pivotal Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback